CEOInterviews.AI
Start App
Try: AI strategy tariffs earnings guidance layoffs interest rates growth

James Foster

Chief Executive Officer, President & Chairman, Charles River Laboratories

Search every verified James Foster interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. On the Charles River Laboratories Q4 2024 earnings call, James Foster addressed several industry challenges. He stated that the company believes "any action to restrict the availability of purpose bred NHPs from Cambodia could have significant and unintended consequences that will impact biomedical research globally," adding that "legally sourced NHPs are critical regulatory required models to help ensure human patient safety." Regarding the company's financial strategy, Foster said that "based on our anticipated capital needs this year and coupled with our belief that we are currently undervalued, it is an opportune time to allocate most of our free cash flow to stock repurchases in 2025," noting an intention to repurchase approximately $350 million in stock over the next month or two. Foster also commented on the broader market environment, saying that while the company had previously assumed conditions would improve in the second half of 2024, "assuming that things are going to get better would all be total speculation at this point." He noted that the company is "really not hearing much from our clients on the RFK situation" and said the company will "have to see how that plays out" regarding potential impacts on drug development and the FDA. On tariffs, Foster remarked that "trying to support US development of drugs... could be beneficial to US drug companies."

Recent appearances

The summary and quote tags on this profile are produced with AI assistance from verified, first-person interview transcripts, then checked by our team to confirm the speaker's identity and the accuracy of every quote. See how we verify →